Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Multiple Sclerosis

Free Subscription Articles published in J Neurol Sci Retrieve available abstracts of 86 articles: HTML format

Single Articles

February 2026
1. UROLAGIN D, Kavyashree MV, Sowmya BA
   Comment on "Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis".
   J Neurol Sci. 2026 Feb 18:125820. doi: 10.1016/j.jns.2026.125820.
   PubMed    
   
   
   
2. ALBITES COEN B, Chowdhury P, Messina SA, Keegan BM, et al
   Brain MRI to detect cervical spinal cord critical demyelinating lesions in progressive MS.
   J Neurol Sci. 2026;481:125761.
   PubMed     Abstract available
   
   
   
3. GUIDO FS, Chen JJ, Decker PA, Fereidan-Esfahani M, et al
   The impact of adding optical coherence tomography in MS diagnostic criteria on the classification of tumefactive demyelination.
   J Neurol Sci. 2026;481:125739.
   PubMed     Abstract available
   
   
   
4. NICOLELLA V, Terracciano D, Moccia M
   Authors response to Comment on "Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis".
   J Neurol Sci. 2026;482:125819.
   PubMed    
   
   
   
5. KARNBROCK L, Herwerth M, Bloemberg GV, Huber M, et al
   Persistent parvovirus B19 DNAemia in B-cell depletion: Implications for family planning in multiple sclerosis and related disorders.
   J Neurol Sci. 2026;482:125796.
   PubMed     Abstract available
   
   
   
6. BAHARNOORI M, Glanz B, Polgar-Turcsanyi M, Saxena S, et al
   Correlation between blood biomarkers and patient-reported outcomes (PROs) of depression and mental health scores in individuals with multiple sclerosis (iwMS).
   J Neurol Sci. 2026;482:125786.
   PubMed     Abstract available
   
   
   January 2026
7. AERTS S, Geys L, Severijns D, Alkhawajah M, et al
   Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews.
   J Neurol Sci. 2026;481:125756.
   PubMed     Abstract available
   
   
   December 2025
8. JAKIMOVSKI D, Bergsland N, Marr K, Dwyer MG, et al
   Lower vascular cerebral flow and cerebral perfusion may be associated with impairment of the glymphatic system in multiple sclerosis: A cross-sectional DTI-ALPS MRI study.
   J Neurol Sci. 2025;480:125709.
   PubMed     Abstract available
   
   
   
9. TYAGI B, Toppo L, Biradar A
   Comment on "wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab".
   J Neurol Sci. 2025;480:125705.
   PubMed    
   
   
   
10. FUCHS L, Avizov R, Karni A, Golan M, et al
    Siponimod enhances brain-derived neurotrophic factor secretion from immune cells in multiple sclerosis: A longitudinal study.
    J Neurol Sci. 2025;480:125699.
    PubMed     Abstract available
    
    
    
11. RANGANI F, Nahayati MA, Pahlevan Kakhki M, Aghaee-Bakhtiari SH, et al
    Ocrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis.
    J Neurol Sci. 2025;480:125693.
    PubMed     Abstract available
    
    
    
12. NICOLELLA V, Varelli M, Fasano S, Cantone E, et al
    Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis.
    J Neurol Sci. 2025;480:125681.
    PubMed     Abstract available
    
    
    November 2025
13. GELISSEN LMY, Hogenboom L, Toorop AA, Strijbis EMM, et al
    Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab.
    J Neurol Sci. 2025;479:125652.
    PubMed     Abstract available
    
    
    
14. CWAJNA M, Hamouda AM, Kendall N, Ghozy S, et al
    Factors influencing timeliness of reporting results from multiple sclerosis related clinical trials to ClinicalTrials.gov.
    J Neurol Sci. 2025;479:123744.
    PubMed     Abstract available
    
    
    October 2025
15. PIEDRABUENA MA, Correale J, Silva B, Fiol M, et al
    Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world study.
    J Neurol Sci. 2025;478:123727.
    PubMed     Abstract available
    
    
    
16. SPIERER R, Hurani M, Stein N, Rawashdeh A, et al
    Trends in prevalence and incidence of multiple sclerosis in the Israeli Jewish and Arab populations.
    J Neurol Sci. 2025;478:123721.
    PubMed     Abstract available
    
    
    September 2025
17. MOODY SN, Manuel M, Willette A, Shirtcliff E, et al
    Corrigendum to "The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis" [Journal of the Neurological Sciences, 466 (2024) 123260].
    J Neurol Sci. 2025;478:123697.
    PubMed    
    
    
    
18. SIPILA J, Jokela M, Solje E
    Municipality-level incidence of clinically diagnosed amyotrophic lateral sclerosis, multiple sclerosis and Parkinson's disease.
    J Neurol Sci. 2025;478:123696.
    PubMed     Abstract available
    
    
    August 2025
19. LADAKIS DC, Ghajarzadeh M, Bhargava P, Absinta M, et al
    Association of paramagnetic rim lesions with patient-reported neuropsychiatric symptoms in multiple sclerosis.
    J Neurol Sci. 2025;477:123657.
    PubMed     Abstract available
    
    
    July 2025
20. ABBADESSA G, Schiavetti I, Bollo L, Cellerino M, et al
    Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective study.
    J Neurol Sci. 2025;474:123533.
    PubMed     Abstract available
    
    
    June 2025
21. GLANZ BI, Kletenik I, Singhal T, Zurawski JD, et al
    Subjective cognitive function in individuals with multiple sclerosis: Associations with objective cognitive function, anxiety, depression, and fatigue.
    J Neurol Sci. 2025;475:123593.
    PubMed     Abstract available
    
    
    
22. KVARTSKHAVA T, Freudenstein D, Sarmiento N, Angstwurm K, et al
    Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2025;475:123577.
    PubMed     Abstract available
    
    
    
23. NOVARELLA F, Nicolella V, Fiorenza M, Falco F, et al
    Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis.
    J Neurol Sci. 2025;475:123562.
    PubMed     Abstract available
    
    
    May 2025
24. DEVOGELAERE J, Van Remoortel A, Van Laethem D, Faille LD, et al
    Impact of brain volume on coronavirus disease of 2019 severity and subsequent cognitive decline in patients with multiple sclerosis.
    J Neurol Sci. 2025;475:123552.
    PubMed     Abstract available
    
    
    
25. NYGAARD MKE, Riemenschneider M, Gaemelke T, Dalgas U, et al
    Spatiotemporal alterations of gray matter microstructure in newly diagnosed relapsing-remitting multiple sclerosis patients: A longitudinal diffusion kurtosis MRI study.
    J Neurol Sci. 2025;474:123551.
    PubMed     Abstract available
    
    
    
26. KELLY H, Sun R, Elkasaby M, Wang A, et al
    Movement disorders in relapsing and progressive MS: A comprehensive prospective evaluation of a large real-life cohort.
    J Neurol Sci. 2025;472:123468.
    PubMed     Abstract available
    
    
    
27. ZIVLAEI N, Asani DC, Trier NH, Ziogiene D, et al
    Virus-specific antibody responses in multiple sclerosis patients treated with Ocrevus.
    J Neurol Sci. 2025;474:123537.
    PubMed     Abstract available
    
    
    
28. BERNTSSON SG, Reis J, Zjukovskaja C, Tulek Z, et al
    Climate change impacts the symptomology and healthcare of multiple sclerosis patients through fatigue and heat sensitivity - A systematic review.
    J Neurol Sci. 2025;474:123526.
    PubMed     Abstract available
    
    
    March 2025
29. RISI M, Altieri M, Bisecco A, Rippa V, et al
    Longitudinal assessment of cognitive function in patients with non-relapsing MOG-IgG associated disease.
    J Neurol Sci. 2025;470:123413.
    PubMed     Abstract available
    
    
    
30. RANGANI F, Rakhshi N, Kadkhoda Mezerji Z, Alikhah A, et al
    Association of IL2RA and multiple sclerosis risk: A case control, systematic review, and meta-analysis study.
    J Neurol Sci. 2025;472:123461.
    PubMed     Abstract available
    
    
    February 2025
31. HELMLINGER B, Seebacher B, Ropele S, Hechenberger S, et al
    Effects of rhythmic-cued gait training on gait-like task related brain activation in people with multiple sclerosis.
    J Neurol Sci. 2025;471:123426.
    PubMed     Abstract available
    
    
    
32. FILIPPATOU A, Theodorou A, Stefanou MI, Tzanetakos D, et al
    Optical coherence tomography and angiography in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2025;470:123422.
    PubMed     Abstract available
    
    
    
33. WANG WS, Xia ZY
    Examining the role of optical coherence tomography in multiple sclerosis research and clinical practice.
    J Neurol Sci. 2025;470:123421.
    PubMed    
    
    
    January 2025
34. YOUNG CA, Rog D, Sharrack B, Chhetri SK, et al
    Clinical and socio-demographic characteristics of people with multiple sclerosis at the time of diagnosis: Influences on outcome trajectories.
    J Neurol Sci. 2025;470:123409.
    PubMed     Abstract available
    
    
    
35. MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al
    The relationship between optical coherence tomography and magnetic resonance imaging measurements in people with multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2025;470:123401.
    PubMed     Abstract available
    
    
    
36. NOCITI V, Romozzi M, Annovazzi P, Fantozzi R, et al
    Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies.
    J Neurol Sci. 2025;469:123392.
    PubMed     Abstract available
    
    
    
37. GOPALAKRISHNAN N, Cadden M, Barker L, Healy BC, et al
    Baseline predictors of cross-sectional and longitudinal performance on the symbol digit modalities test in individuals with multiple sclerosis.
    J Neurol Sci. 2025;469:123384.
    PubMed     Abstract available
    
    
    
38. ENGELS D, Flierl-Hecht A, Shalaginova G, Rek S, et al
    Multiple sclerosis twin study reveals distinct genetic, disease-specific, and psychometric impact on coping with critical life events.
    J Neurol Sci. 2025;469:123381.
    PubMed     Abstract available
    
    
    December 2024
39. D'CUNHA MA, Pandit L, Sudhir A
    MRZ-reaction maybe influenced by immunization status and is not exclusive to multiple sclerosis.
    J Neurol Sci. 2024;468:123365.
    PubMed     Abstract available
    
    
    
40. MIMORI M, Katsumoto A, Okamoto T, Sato W, et al
    Ofatumumab for multiple sclerosis with disability accumulation.
    J Neurol Sci. 2024;468:123356.
    PubMed     Abstract available
    
    
    November 2024
41. NOMURA T, Muramatsu K, Yaguchi H, Uwatoko H, et al
    Three cases of multiple sclerosis presenting with palmoplantar pustulosis while receiving ofatumumab.
    J Neurol Sci. 2024;467:123315.
    PubMed    
    
    
    
42. KORNILOV SA, Price ND, Gelinas R, Acosta J, et al
    Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2024;467:123303.
    PubMed     Abstract available
    
    
    September 2024
43. MOODY SN, Manuel M, Willette A, Shirtcliff E, et al
    The intersection of race and sex on the clinical and cognitive progression of multiple sclerosis.
    J Neurol Sci. 2024;466:123260.
    PubMed     Abstract available
    
    
    
44. DOHERTY F, Lynch P, Powell P, Monaghan K, et al
    Feasibility and effectiveness of telerehabilitation on mobility and balance function in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2024;466:123214.
    PubMed     Abstract available
    
    
    August 2024
45. AFZAL SS, Khatri I, Amin SB
    Comment on: Evaluation of the T25FW in minimally disabled people with multiple sclerosis.
    J Neurol Sci. 2024 Aug 22:123189. doi: 10.1016/j.jns.2024.123189.
    PubMed    
    
    
    
46. PATEL AM, Exuzides A, Yermilov I, Dalglish H, et al
    Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorder.
    J Neurol Sci. 2024;463:123110.
    PubMed     Abstract available
    
    
    
47. CHAPPELL M, Sanderson A, Arun T, Green C, et al
    Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the 'suboptimal therapy' patient population.
    J Neurol Sci. 2024;464:123172.
    PubMed     Abstract available
    
    
    
48. GOUIDER R, Souissi A, Mrabet S, Gharbi A, et al
    Environmental factors related to multiple sclerosis progression.
    J Neurol Sci. 2024;464:123161.
    PubMed     Abstract available
    
    
    July 2024
49. WICKS TR, Jakimovski D, Reeves J, Bergsland N, et al
    Comorbid onset of cardiovascular diagnosis and long-term confirmed disability progression in multiple sclerosis: A 15-year follow-up study.
    J Neurol Sci. 2024;464:123156.
    PubMed     Abstract available
    
    
    
50. TOOROP AA, Wessels MHJ, Gelissen LMY, Hoitsma E, et al
    Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
    J Neurol Sci. 2024;462:123102.
    PubMed     Abstract available
    
    
    
51. PETROVSKA J, Coynel D, Freytag V, de Quervain DJ, et al
    Polygenic susceptibility for multiple sclerosis is associated with working memory in low-performing young adults.
    J Neurol Sci. 2024;463:123138.
    PubMed     Abstract available
    
    
    
52. NIKITINA V, Santi Laurini G, Montanaro N, Motola D, et al
    Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database.
    J Neurol Sci. 2024;463:123132.
    PubMed     Abstract available
    
    
    June 2024
53. NICOLELLA V, Fiorenza M, Monteiro I, Novarella F, et al
    Clinical utility of the Lumipulse immunoassay for plasma neurofilament light chain in multiple sclerosis.
    J Neurol Sci. 2024;463:123115.
    PubMed     Abstract available
    
    
    
54. TRIVEDI RR, Archambault AS, Pavlak C, Gastaldi M, et al
    Prevalence of anti-myelin oligodendrocyte glycoprotein antibodies across neuroinflammatory and neurodegenerative diseases.
    J Neurol Sci. 2024;461:123041.
    PubMed     Abstract available
    
    
    
55. HILDEBRANDT H, Eling P
    Comments on energy conservation treatments for MS-related fatigue and a new proposal.
    J Neurol Sci. 2024;461:123040.
    PubMed     Abstract available
    
    
    
56. HELMLINGER B, Pinter D, Hechenberger S, Bachmaier G, et al
    Evaluation of the T25FW in minimally disabled people with multiple sclerosis.
    J Neurol Sci. 2024;462:123073.
    PubMed     Abstract available
    
    
    May 2024
57. FERNANDES L, Coats RO, Mon-Williams M, Hafeez A, et al
    A novel tool for characterising upper limb function in progressive multiple sclerosis through kinematic assessment.
    J Neurol Sci. 2024;462:123068.
    PubMed     Abstract available
    
    
    
58. MANNI A, Oggiano F, Palazzo C, Panetta V, et al
    Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing.
    J Neurol Sci. 2024;462:123070.
    PubMed     Abstract available
    
    
    
59. LOREFICE L, Piras C, Sechi V, Barracciu MA, et al
    Spinal cord MRI activity in multiple sclerosis: Predictive value for relapses and impact on treatment decisions.
    J Neurol Sci. 2024;462:123057.
    PubMed     Abstract available
    
    
    
60. PIEDRABUENA MA, Correale J, Fiol M, Marrodan M, et al
    Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.
    J Neurol Sci. 2024;461:123052.
    PubMed     Abstract available
    
    
    
61. JAKIMOVSKI D, Qureshi F, Ramanathan M, Jalaleddini K, et al
    Glial cell injury and atrophied lesion volume as measures of chronic multiple sclerosis inflammation.
    J Neurol Sci. 2024;461:123055.
    PubMed     Abstract available
    
    
    
62. SKARLIS C, Papadopoulos V, Raftopoulou S, Mavragani CP, et al
    Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    J Neurol Sci. 2024;461:123046.
    PubMed     Abstract available
    
    
    March 2024
63. CHAER LER, de Mendonca JM, Del Negro MC, Titze-de-Almeida R, et al
    Differential diagnosis between multiple sclerosis and leukodystrophies - A scoping review.
    J Neurol Sci. 2024;459:122969.
    PubMed     Abstract available
    
    
    
64. BERNARDES C, Fernandes C, Cunha C, Nunes C, et al
    Natalizumab extended interval dosing: what about wearing-off effect?
    J Neurol Sci. 2024;458:122930.
    PubMed     Abstract available
    
    
    February 2024
65. RECHTMAN A, Zveik O, Haham N, Freidman-Korn T, et al
    Thyroid hormone dysfunction in MOGAD and other demyelinating diseases.
    J Neurol Sci. 2024;457:122866.
    PubMed     Abstract available
    
    
    
66. BALCOM EF, Smyth P, Kate M, Vu K, et al
    Disease-modifying therapy use and health resource utilisation associated with multiple sclerosis over time: A retrospective cohort study from Alberta, Canada.
    J Neurol Sci. 2024;458:122913.
    PubMed     Abstract available
    
    
    
67. KUSNIRIKOVA ZK, Kacirova I, Pesakova V, Hradilek P, et al
    Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study.
    J Neurol Sci. 2024;458:122910.
    PubMed     Abstract available
    
    
    January 2024
68. ZANETTA C, Faustino P, Guerrieri S, Nozzolillo A, et al
    Fast but not furious: Rapid ocrelizumab infusion as a strategy to optimize multiple sclerosis patients' management.
    J Neurol Sci. 2024;457:122897.
    PubMed     Abstract available
    
    
    
69. MOTEGI H, Kufukihara K, Kitagawa S, Sekiguchi K, et al
    Non-lesional white matter changes depicted by q-space diffusional MRI correlate with clinical disabilities in multiple sclerosis.
    J Neurol Sci. 2024;456:122851.
    PubMed     Abstract available
    
    
    
70. HJAERESEN S, Benedikz E, Sejbaek T, Axelsson M, et al
    High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
    J Neurol Sci. 2024;457:122888.
    PubMed     Abstract available
    
    
    
71. RAGHIB MF, Bao F, Elkhooly M, Bernitsas E, et al
    Choroid plexus volume as a marker of retinal atrophy in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2024;457:122884.
    PubMed     Abstract available
    
    
    December 2023
72. KREITER D, Postma AA, Hupperts R, Gerlach O, et al
    Hallmarks of spinal cord pathology in multiple sclerosis.
    J Neurol Sci. 2023;456:122846.
    PubMed     Abstract available
    
    
    
73. MARANTOS T, Kyriazopoulou E, Lekakis V, Voumvourakis KI, et al
    Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2023;456:122852.
    PubMed     Abstract available
    
    
    
74. DOHERTY F, Powell P, McBride C, Monaghan K, et al
    Physical Telerehabilitation interventions for Gait and balance in Multiple sclerosis: A Scoping review.
    J Neurol Sci. 2023;456:122827.
    PubMed     Abstract available
    
    
    November 2023
75. KHORMI I, Al-Iedani O, Alshehri A, Ramadan S, et al
    MR myelin imaging in multiple sclerosis: A scoping review.
    J Neurol Sci. 2023;455:122807.
    PubMed     Abstract available
    
    
    
76. JAKIMOVSKI D, Kavak KS, Zakalik K, McGraw C, et al
    Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study.
    J Neurol Sci. 2023;455:122781.
    PubMed     Abstract available
    
    
    
77. DITTEL LJ, Dittel BN, Brod SA
    Ingested (oral) adrenocorticotropic hormone (ACTH) inhibits interleukin-17 in the central nervous system after adoptive transfer of T helper (Th)1/Th17 T cells in the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis.
    J Neurol Sci. 2023;456:122779.
    PubMed     Abstract available
    
    
    October 2023
78. MIRMOSAYYEB O, Yazdan Panah M, Mokary Y, Ghaffary EM, et al
    Optical coherence tomography (OCT) measurements and disability in multiple sclerosis (MS): A systematic review and meta-analysis.
    J Neurol Sci. 2023;454:120847.
    PubMed     Abstract available
    
    
    
79. HECHENBERGER S, Helmlinger B, Penner IK, Pirpamer L, et al
    Psychological factors and brain magnetic resonance imaging metrics associated with fatigue in persons with multiple sclerosis.
    J Neurol Sci. 2023;454:120833.
    PubMed     Abstract available
    
    
    September 2023
80. DE LURY AD, Bisulca JA, Lee JS, Altaf MD, et al
    Magnetic resonance imaging detection of deep gray matter iron deposition in multiple sclerosis: A systematic review.
    J Neurol Sci. 2023;453:120816.
    PubMed     Abstract available
    
    
    
81. MUSTAFA R, Flanagan EP, Duffy DJ, Weinshenker BG, et al
    Laboratory evaluation for the differential diagnosis of possible multiple sclerosis in the United States: A physician survey.
    J Neurol Sci. 2023;453:120781.
    PubMed     Abstract available
    
    
    August 2023
82. OSEN A, Stefoski D, Shoemaker T, Kaplan T, et al
    Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders.
    J Neurol Sci. 2023;451:120693.
    PubMed     Abstract available
    
    
    July 2023
83. PATIL SA, Joseph B, Tagliani P, Sastre-Garriga J, et al
    Corrigendum to "Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis" [Journal of the Neurological Sciences 449C (2023) Start page-End page/JOTNS
    J Neurol Sci. 2023 Jul 17:120695. doi: 10.1016/j.jns.2023.120695.
    PubMed    
    
    
    
84. JEANTIN L, Boudot de la Motte M, Deschamps R, Gueguen A, et al
    Natalizumab extended-interval dosing in a real-life setting.
    J Neurol Sci. 2023;450:120689.
    PubMed     Abstract available
    
    
    
85. WEBB LM, Cacciaguerra L, Krecke KN, Chen JJ, et al
    Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS.
    J Neurol Sci. 2023;450:120687.
    PubMed     Abstract available
    
    
    May 2023
86. PATIL SA, Joseph B, Tagliani P, Sastre-Garriga J, et al
    Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis.
    J Neurol Sci. 2023;449:120669.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum